pizuglanstat (TAS-205) / Otsuka 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
  • ||||||||||  pizuglanstat (TAS-205) / Otsuka
    Journal:  Structure-activity relationship study of PROTACs against hematopoietic prostaglandin D synthase. (Pubmed Central) -  Dec 24, 2022   
    All compounds showed high H-PGDS degrading activities, but PROTAC(H-PGDS)-4-TAS-205 (PROTAC3) was slightly less active than the other compounds. Molecular dynamics simulations suggested that the decrease in activity of PROTAC3 may be due to the lower stability of the CRBN-PROTAC-H-PGDS ternary complex.
  • ||||||||||  Journal:  Perspectives on the advances in the pharmacotherapeutic management of Duchenne muscular dystrophy. (Pubmed Central) -  Nov 5, 2022   
    Corticosteroids such as prednisone and deflazacort are routinely given to patients to treat inflammation, but their use is limited by the occurrence of side effects and a lack of standardized prescribing...Excessive cost is a barrier to patients receiving medications that have yet to have established efficacy. Additional therapies have the potential to help patients with DMD, although most are several years away from approval for patient use.
  • ||||||||||  pizuglanstat (TAS-205) / Otsuka
    Trial completion:  Mass Balance Study of [14C] TAS-205 in Healthy Volunteers (clinicaltrials.gov) -  Aug 8, 2022   
    P1,  N=6, Completed, 
    Additional therapies have the potential to help patients with DMD, although most are several years away from approval for patient use. Active, not recruiting --> Completed
  • ||||||||||  pizuglanstat (TAS-205) / Otsuka
    Trial primary completion date:  Mass Balance Study of [14C] TAS-205 in Healthy Volunteers (clinicaltrials.gov) -  Feb 2, 2022   
    P1,  N=6, Active, not recruiting, 
    This study provides a current summary of prognostic indicators of disease progression in DMD, which will help inform the design of comparative analyses and future data collection initiatives in this patient population. Trial primary completion date: Apr 2022 --> Jun 2021
  • ||||||||||  pizuglanstat (TAS-205) / Otsuka
    Enrollment closed:  Mass Balance Study of [14C] TAS-205 in Healthy Volunteers (clinicaltrials.gov) -  Aug 19, 2021   
    P1,  N=6, Active, not recruiting, 
    Further research is required to examine the effectiveness of TAS-205 in a larger trial. Not yet recruiting --> Active, not recruiting
  • ||||||||||  pizuglanstat (TAS-205) / Otsuka
    Trial completion, Trial completion date, Trial primary completion date:  A Phase IIa Study of TAS-205 for Duchenne Muscular Dystrophy (clinicaltrials.gov) -  Feb 6, 2018   
    P2a,  N=33, Completed, 
    These results suggest that combined treatment with an HPGDS inhibitor and different types of anti-allergic medicine may be a promising strategy to control nasal obstruction in AR patients. Active, not recruiting --> Completed | Trial completion date: Oct 2017 --> Oct 2017 | Trial primary completion date: May 2017 --> May 2017
  • ||||||||||  pizuglanstat (TAS-205) / Otsuka
    Enrollment closed:  A Phase IIa Study of TAS-205 for Duchenne Muscular Dystrophy (clinicaltrials.gov) -  Dec 28, 2016   
    P2a,  N=33, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Oct 2017 --> Oct 2017 | Trial primary completion date: May 2017 --> May 2017 Recruiting --> Active, not recruiting
  • ||||||||||  pizuglanstat (TAS-205) / Otsuka
    Enrollment open:  A Phase IIa Study of TAS-205 for Duchenne Muscular Dystrophy (clinicaltrials.gov) -  May 26, 2016   
    P2a,  N=33, Recruiting, 
    Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
  • ||||||||||  pizuglanstat (TAS-205) / Otsuka
    Trial completion:  A Study of TAS-205 for Duchenne Muscular Dystrophy (clinicaltrials.gov) -  Sep 25, 2015   
    P1,  N=21, Completed, 
    Not yet recruiting --> Recruiting Active, not recruiting --> Completed
  • ||||||||||  pizuglanstat (TAS-205) / Otsuka
    Enrollment closed:  A Study of TAS-205 for Duchenne Muscular Dystrophy (clinicaltrials.gov) -  Jul 8, 2015   
    P1,  N=21, Active, not recruiting, 
    Active, not recruiting --> Completed Recruiting --> Active, not recruiting
  • ||||||||||  pizuglanstat (TAS-205) / Otsuka
    Enrollment open:  A Study of TAS-205 for Duchenne Muscular Dystrophy (clinicaltrials.gov) -  Oct 17, 2014   
    P1,  N=21, Recruiting, 
    Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting